A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type
1 and type 2 narcolepsy from previous parent studies, TAK-861-2001 (NCT05687903) and
TAK-861-2002 (NCT05687916).